News & Updates
Filter by Specialty:
Sotatercept: A first-in-class PAH medication approved in HK
Sotatercept, a first-in-class acÂtivin signalling inhibitor for pulÂmonary arterial hypertension (PAH), is approved in Hong Kong in August 2025, following regulatory apÂprovals in Macau, the US, and the EU in February 2025.
Sotatercept: A first-in-class PAH medication approved in HK
20 Aug 2025
Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler
Once-daily, single-inhaler triple therapy with fluticasone fuÂroate/umeclidinium/vilanterÂol (FF/UMEC/VI) outperforms twice-daily, single-inhaler triple therapy with budesonide/glycopyrrolate/forÂmoterol fumarate (BUD/GLY/ FORM) in the treatment of chronÂic obstructive pulmonary disease (COPD), two recent real-world comparative effectiveness studies have found.
Real-world data: FF/UMEC/VI offers clinical advantages over another 3-in-1 COPD inhaler
20 Aug 2025
Can fasting and a no-sugar diet alleviate long COVID symptoms?
In a crossover trial evaluating the effect of two intermittent fasting (IF) regimens on long COVID (LC) symptoms, a daily 16-h fast with water-only fast and a no-sugar diet fared better than a daily 14-h time-restricted eating (TRE) regimen for mitigating long COVID symptoms.
Can fasting and a no-sugar diet alleviate long COVID symptoms?
19 Aug 2025
Multimorbidity, frailty up risk of COPD readmission
Frailty and multimorbidity may increase the likelihood of being readmitted within 30 days following an index admmission among patients with chronic obstructive pulmonary disease (COPD), reveals a Singapore study.
